产品描述
| 溶解性 | Soluble in DMSO (100 mg/ml at 25 °C), ethanol (<1 mg/ml at 25 °C), DMF (~5 mg/ml), water (<1 mg/ml at 25 °C), and 0.5% methylcellulose (30 mg/ml at 25 °C). |
| 应用 | A selective JAK3 inhibitor |
| 产品介绍 | Tofacitinib (CP-690550) Citrate是一种新型JAK3抑制剂，IC50为1 nM，作用于JAK2和JAK1选择性比其低20到100倍。 |
| 合法信息 | Sold for only research purposes |
| 备注 | Tofacitinib citrate (CP-690550 citrate) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1. Phase 3. |
| 生化机理 | Tofacitinib is a potent inhibitor of JAK3 (Janus kinase 3) with some JAK1 inhibitory activity as well. JAK3 blocks downstream STAT signaling resulting in potent inhibition of inflammatory cytokines with resultant immunosuppressive and anti-inflammatory activity. |
| 别名 | 枸橼酸托法替尼;枸橼酸托法替布;CP 690550 枸橼酸盐;(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile citrate salt ;3-[(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile citrate salt; CP-690550-10; Tasocitinib citrate salt;Tofacitinib citrate;CP-690550 citrate; CP 690550 citrate; CP690550 citrate |
